Even though IL-5 is a key regulatory cytokine of eosinophils that is upregulated in EoE, anti-IL-5 therapy using two different humanized monoclonal antibodies partially reduces tissue eosinophilia but does not alter esophageal fibrosis (132, 133). Here, IL5 is linked to eosinophilic esophagitis.